Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas is a PHASE1 clinical asset sponsored by Silenseed Ltd in Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer. SEO and diligence focus: siG12D LODER, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.